Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rang in Aktien #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aktienkurs
$0.25974701
Zuletzt synchronisiert: 2025-01-06
Marktkapitalisierung
$2.04M
Veränderung (1 Tag)
0.74%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategorie

Kursverlauf für Acticor Biotech SAS (ALACT)
Höchster Schlusskurs: $0.26 am 2025-01-01

Niedrigster Schlusskurs: $7.56 am 2021-11-01
Kursverlauf der Aktie von Acticor Biotech SAS von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2025 -4.45%
2024 -91.43%
2023 -58.60%
2022 31.92%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$515.26 31.04%
US
$987.98 30.54%
NL
$122.35 -10.30%
AU
$142.87 498.26%
US
$697.62 1.32%
CH